Tecvayli + Darzalex Faspro achieves 100% MRD negativity in newly diagnosed MM, phase II study shows

Northwell, START unveil $5.7M early-phase clinical trial center

Credit: Northwell Health.Northwell Health and START Center for Cancer Research have unveiled a $5.7M, 10,000 square foot early-phase cancer clinical trial center that aims to provide better access to treatments for cancer patients in New York and Long Island.

December 19, 2025

Vol.51 No.46

In Brief

Khalil Choucair joins thoracic oncology and phase I clinical trials teams at Karmanos

Khalil Choucair has joined the thoracic oncology and phase I clinical trials multidisciplinary teams as a medical oncologist at Karamos Cancer Institute.

December 19, 2025

Vol.51 No.46

Clinical Roundup

Retifanlimab-dlwr demonstrates 11-month OS difference for anal cancer patients in phase III trial

Researchers presented updated data at ESMO IO from the phase III POD1UM-303/InterAACT 2 trial of retifanlimab-dlwr (Zynyz) in combination with platinum-based chemotherapy (carboplatin and paclitaxel) in adult patients with squamous cell carcinoma of the anal canal.

December 19, 2025

Vol.51 No.46

Clinical Roundup

Mental health conditions increase liver cancer risk in veterans, UCLA-led study finds

Mental health conditions are common among veterans and may play a larger role than previously recognized in raising liver cancer risk for those with hepatitis C.

December 12, 2025

Vol.51 No.45

Fixing site reads without burning out the readers
Yunu modernizes clinical trial imaging assessment workflows

Imaging assessments are a requirement for most oncology trial endpoints. Yet, many cancer centers are still trying to support research trials with clinical care tools and ad hoc processes that are not fit-for-purpose and don’t meet the needs of sponsors or trial staff.

Trump cuts disrupted 383 clinical trials, affecting 74,000 trial participants

Approximately one in 30 NIH-funded clinical trials—and more than 74,000 trial participants—were affected by grant funding disruptions caused by the Trump administration, according to an analysis in JAMA Internal Medicine.

November 21, 2025

Vol.51 No.43

By Jacquelyn Cobb

Tecvayli + Darzalex Faspro achieves 100% MRD negativity in newly diagnosed MM, phase II study shows

YOU MAY BE INTERESTED IN

Northwell, START unveil $5.7M early-phase clinical trial center

Khalil Choucair joins thoracic oncology and phase I clinical trials teams at Karmanos

Retifanlimab-dlwr demonstrates 11-month OS difference for anal cancer patients in phase III trial

Mental health conditions increase liver cancer risk in veterans, UCLA-led study finds

Fixing site reads without burning out the readers
Yunu modernizes clinical trial imaging assessment workflows

Trump cuts disrupted 383 clinical trials, affecting 74,000 trial participants

Renew today!

Subscriber content

Never miss an issue!

Login

Tecvayli + Darzalex Faspro achieves 100% MRD negativity in newly diagnosed MM, phase II study shows

YOU MAY BE INTERESTED IN

Northwell, START unveil $5.7M early-phase clinical trial center

Khalil Choucair joins thoracic oncology and phase I clinical trials teams at Karmanos

Retifanlimab-dlwr demonstrates 11-month OS difference for anal cancer patients in phase III trial

Mental health conditions increase liver cancer risk in veterans, UCLA-led study finds

Fixing site reads without burning out the readersYunu modernizes clinical trial imaging assessment workflows

Trump cuts disrupted 383 clinical trials, affecting 74,000 trial participants

Never miss an issue!

Login

Fixing site reads without burning out the readers
Yunu modernizes clinical trial imaging assessment workflows